Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [BUSINESS]
2 clusters · 3 sources · 3 days · First seen · Last updated
Biotechnology executive stock sales
Overview
Executives at various biotechnology firms have engaged in significant stock sales.
At Spyre Therapeutics, the Chief Financial Officer, Chief Legal Officer, and CEO sold shares totaling several million dollars. These transactions, including approximately $1.57 million by CFO Scott Burrows and $2.63 million by Chief Legal Officer Heidy King-Jones, were executed under pre-arranged Rule 10b5-1 trading plans following a period of stock price appreciation.
Similarly, three top executives at Corcept Therapeutics sold shares totaling approximately $5 million. These sales, involving the President of Corcept Endocrinology, the Chief Accounting & Technology Officer, and the President of Oncology, were also conducted under 10b5-1 trading plans as the company’s stock approached a yearly high.
Entities
Joseph Douglas Lyon · Scott Burrows · Sean Maduck · Spyre Therapeutics, Inc. · Heidy King-Jones
Timeline
-
[BUSINESS] 3 sourcesCorcept Therapeutics executives sell $5 million in stock
Three Corcept Therapeutics executives sold approximately $5 million in stock via pre-scheduled 10b5-1 plans amid a recent surge in the company's share price.
-
[BUSINESS] 2 sourcesSpyre Therapeutics executives sell millions in stock
Top executives at Spyre Therapeutics, including the CEO, CFO, and CLO, have sold millions of dollars in company stock through pre-arranged Rule 10b5-1 trading plans.
Sources
ad-hoc-news.de · finanzen.ch · stocknews.com